当前位置：
X-MOL 学术
›
WIREs Nanomed. Nanobiotechnol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Current development of cabazitaxel drug delivery systems
WIREs Nanomedicine and Nanobiotechnology ( IF 6.9 ) Pub Date : 2022-09-25 , DOI: 10.1002/wnan.1854 Boyang Sun 1 , Jonathan F Lovell 2 , Yumiao Zhang 1
WIREs Nanomedicine and Nanobiotechnology ( IF 6.9 ) Pub Date : 2022-09-25 , DOI: 10.1002/wnan.1854 Boyang Sun 1 , Jonathan F Lovell 2 , Yumiao Zhang 1
Affiliation
|
The second-generation taxane cabazitaxel has been clinically approved for the treatment of metastatic castration-resistant prostate cancer after docetaxel failure. Compared with the first-generation taxanes paclitaxel and docetaxel, cabazitaxel has potent anticancer activity and is less prone to drug resistance due to its lower affinity for the P-gp efflux pump. The relatively high hydrophobicity of cabazitaxel and the poor aqueous colloidal stability of the commercial formulation, following its preparation for injection, presents opportunities for new cabazitaxel formulations with improved features. This review provides an overview of cabazitaxel drug formulations and hydrophobic taxane drug delivery systems in general, and particularly focuses on emerging cabazitaxel delivery systems discovered in the past 5 years.
中文翻译：
卡巴他赛给药系统的发展现状
第二代紫杉烷类卡巴他赛已获临床批准用于治疗多西他赛治疗失败后的转移性去势抵抗性前列腺癌。与第一代紫杉烷类紫杉醇和多西紫杉醇相比，卡巴他赛抗癌活性强，且与P-gp外排泵的亲和力较低，不易产生耐药性。卡巴他赛相对较高的疏水性和商业制剂较差的水性胶体稳定性，在其制备用于注射后，为开发具有改进特性的新卡巴他赛制剂提供了机会。本综述概述了卡巴他赛药物制剂和疏水性紫杉烷药物输送系统的总体情况，并特别关注了过去 5 年发现的新兴卡巴他赛输送系统。
更新日期：2022-09-25
中文翻译：
卡巴他赛给药系统的发展现状
第二代紫杉烷类卡巴他赛已获临床批准用于治疗多西他赛治疗失败后的转移性去势抵抗性前列腺癌。与第一代紫杉烷类紫杉醇和多西紫杉醇相比，卡巴他赛抗癌活性强，且与P-gp外排泵的亲和力较低，不易产生耐药性。卡巴他赛相对较高的疏水性和商业制剂较差的水性胶体稳定性，在其制备用于注射后，为开发具有改进特性的新卡巴他赛制剂提供了机会。本综述概述了卡巴他赛药物制剂和疏水性紫杉烷药物输送系统的总体情况，并特别关注了过去 5 年发现的新兴卡巴他赛输送系统。
京公网安备 11010802027423号